Review of guideline for the management of ANCA-associated vasculitis, presented in 2021 by the American College of Rheumatology/Vasculitis Foundation
https://doi.org/10.47360/1995-4484-2021-684-692
Abstract
The anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAVs) are a group of severe life-threatening autoimmune diseases, and one of the most important problems in practical rheumatology. This article discusses 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of AAVs, including granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA). The guideline features 26 recommendations and 5 upgraded position statements for GPA/ MPA, as well as 15 recommendations and 5 upgraded position statements for EGPA, which became the basis for the proposed algorithms for the treatment of patients with GPA/MPA and EGPA. Particular attention has been paid to the use of biologics.
About the Authors
T. V. Beketova
V.A. Nasonova Research Institute of Rheumatology; Central Clinical Hospital of the Administrative Directorate of the President of the Russian Federation
Russian Federation
Competing Interests:
Russian Federation
Tatiana V. Beketova.
115522, Moscow, Kashirskoye Highway, 34A; 121359, Moscow, Marshala Timoshenko str., 15.
Competing Interests:
No
I. Yu. Popov
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Competing Interests:
Russian Federation
Ivan Yu. Popov.
115522, Moscow, Kashirskoye Highway, 34A.
Competing Interests:
No
V. V. Babak
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Competing Interests:
Russian Federation
Valeriya V. Babak.
115522, Moscow, Kashirskoye Highway, 34A.
Competing Interests:
No
References
1. Chung SA, Langford CA, Maz M, Abril A, Gorelik M, Guyatt G, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol. 2021;73(8):1366-1383. doi: 10.1002/art.41773
2. Guillevin L, Pagnoux C, Seror R, Mahr A, Mouthon L, Toumelin PL; French Vasculitis Study Group (FVSG). The Five-Factor Score revisited: Assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore). 2011;90(1):19-27. doi: 10.1097/MD.0b013e318205a4c6
3. Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al.; RAVE-ITN Research Group. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363(3):221-232. doi: 10.1056/NEJMoa0909905
4. Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, et al.; European Vasculitis Study Group. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010;363(3):211-220. doi: 10.1056/NEJMoa0909169
5. Kahn JE, Grandpeix-Guyodo C, Marroun I, Catherinot E, Mellot F, Roufosse F, et al. Sustained response to mepolizumab in refractory Churg - Strauss syndrome. J Allergy Clin Immunol. 2010;125(1):267-270. doi: 10.1016/j.jaci.2009.10.014
6. Wechsler ME, Akuthota P, Jayne D, Khoury P, Klion A, Langford CA, et al. Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N Engl J Med. 2017;376(20):1921-1932. doi: 10.1056/NEJMoa1702079
7. Menditto VG, Rossetti G, Olivari D, Angeletti A, Rocchi M, Gabrielli A, et al. Rituximab for eosinophilic granulomatosis with polyangiitis: A systematic review of observational studies. Rheumatol. 2021;60:1640-1650. doi: 10.1093/rheumatology/keab046
8. Akiyama M, Kaneko Y, Takeuchi T. Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis: A systematic literature review. Autoimmun Rev. 2021;20:102737. doi: 10.1016/j.autrev.2020.102737
9. Walsh M, Merkel PA, Peh CA, Szpirt WM, Putehal X, Fujimoto S, et al. Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N Engl J Med. 2020;382:622-631. doi: 10.1056/NEJMoa1803537
10. Jayne DR, Gaskin G, Rasmussen N, Abramowicz D, Ferrario F, Guillevin L, et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol. 2007;18:2180-2188. doi: 10.1681/ASN.2007010090
11. Walsh M, Casian A, Flossmann O, Westman K, Hoglund P, Pusey C, et al.; European Vasculitis Study Group (EUVAS). Long-term follow-up of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear. Kidney Int. 2013;84(2):397-402. doi: 10.1038/ki.2013.131
12. Teixeira V, Mohammad AJ, Jones RB, Smith R, Jayne D. Efficacy and safety of rituximab in the treatment of eosinophilic granulomatosis with polyangiitis. RMD Open. 2019;5(1):e000905. doi: 10.1136/rmdopen-2019-000905
13. Crickx E, Machelart I, Lazaro E, Kahn JE, Cohen-Aubart F, Martin T, et al. Intravenous immunoglobulin as an immunomodulating agent in antineutrophil cytoplasmic antibody-associated vas-culitides: A French nationwide study of ninety-two patients. Arthritis Rheumatol. 2016;68:702-712. doi: 10.1002/art.39472
14. De Groot K, Rasmussen N, Bacon PA, Tervaert JW, Feighery C, Gregorini G, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2005;52:2461-2469. doi: 10.1002/art.21142
15. Guillevin L, Pagnoux C, Karras A, Khouatra C, Aumaitre O, Cohen P, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med. 2014;371:1771-1780. doi: 10.1056/NEJMoa1404231
16. Pagnoux C, Mahr A, Hamidou MA, Boffa JJ, Ruivard M, Ducroix JP, et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med. 2008;359:2790-2803. doi: 10.1056/NEJMoa0802311
17. Hiemstra TF, Walsh M, Mahr A, Savage CO, de Groot K, Harper L, et al. Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: A randomized controlled trial. JAMA. 2010;304:2381-2388. doi: 10.1001/jama.2010.1658
18. Puéchal X, Pagnoux C, Baron G, Quémeneur T, Néel A, Agard C, et al. Adding azathioprine to remission-induction glucocorticoids for eosinophilic granulomatosis with polyangiitis (Churg - Strauss), microscopic polyangiitis, or polyarteritis nodosa without poor prognosis factors: A randomized, controlled trial. Arthritis Rheumatol. 2017;69:2175-2186. doi: 10.1002/art.40205
19. Metzler C, Miehle N, Manger K, Iking-Konert C, de Groot K, Hellmich B, et al. Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis. Rheumatology (Oxford). 2007;46:1087-1091. doi: 10.1093/rheumatology/kem029
20. Kado R, Sanders G, McCune WJ. Diagnostic and therapeutic considerations in patients with hypogammaglobulinemia after rituximab therapy (review). Curr Opin Rheumatol. 2017;29:228-233. doi: 10.1097/BOR.0000000000000377
21. Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371:1198-1207. doi: 10.1056/NEJMoa1403290
22. Joshi L, Tanna A, McAdoo SP, Medjeral-Thomas N, Taylor SR, Sandhu G, et al. Long-term outcomes of rituximab therapy in ocular granulomatosis with polyangiitis: Impact on localized and nonlocalized disease. Ophthalmology. 2015;122:1262-1268. doi: 10.1016/j.ophtha.2015.01.016
23. Durel CA, Hot A, Trefond L, Aumaitre O, Pugnet G, Samson M, et al. Orbital mass in ANCA-associated vasculitides: Data on clinical, biological, radiological and histological presentation, therapeutic management, and outcome from 59 patients. Rheumatology (Oxford). 2019;58:1565-1573. doi: 10.1093/rheumatology/Kez071
24. Girard C, Charles P, Terrier B, Bussonne G, Cohen P, Pagnoux C, et al. Tracheobronchial stenoses in granulomatosis with polyangiitis (Wegener's): A report on 26 cases. Medicine (Baltimore). 2015;94:e1088. doi: 10.1097/MD.0000000000001088
25. Sagmeister MS, Grigorescu M, Schonermarck U. Kidney transplantation in ANCA-associated vasculitis. J Nephrol. 2019;32:919-926. doi: 10.1007/s40620-019-00642-x
26. Geetha D, Eirin A, True K, Valentina Irazabal M, Specks U, Seo P, et al. Renal transplantation in antineutrophil cytoplasmic antibody-associated vasculitis: A multicenter experience. Transplantation. 2011;91:1370-1375. doi: 10.1097/TP.0b013e31821ab9aa
27. Sachse F, Stoll W. Nasal surgery in patients with systemic disorders. GMS Curr Top Otorhinolaryngol Head Neck Surg. 2010;9:Doc02. doi: 10.3205/cto000066
28. Congdon D, Sherris DA, Specks U, McDonald T. Long-term follow-up of repair of external nasal deformities in patients with Wegener's granulomatosis. Laryngoscope. 2002;112:731-737. doi: 10.1097/00005537-200204000-00025
29. Tomasson G, Grayson PC, Mahr AD, Lavalley M, Merkel PA. Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis - A meta-analysis. Rheumatology (Oxford). 2012;51(1):100-109. doi: 10.1093/rheumatology/ker280
30. Charles P, Terrier B, Perrodeau E, Cohen P, Faguer S, Huart A, et al. Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: Results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). Ann Rheum Dis. 2018;77:1143-1149. doi: 10.1136/annrheumdis-2017-212878
Review
For citations:
Beketova T.V., Popov I.Yu., Babak V.V. Review of guideline for the management of ANCA-associated vasculitis, presented in 2021 by the American College of Rheumatology/Vasculitis Foundation. Rheumatology Science and Practice. 2021;59(6):684-692. (In Russ.) https://doi.org/10.47360/1995-4484-2021-684-692
Views:
2648
Email this article 